Back to results
US 11,883,490 B2Granted
Induction of IL-12 using immunotherapy
AssigneeMirror Biologics, Inc.
InventorMichael Har-Noy
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods that promote the induction of IL-12 in a patient. The composition includes activated allogeneic cells that are administered to a patient with a disease such as cancer. Administration of the composition skews the patient's immune response to a Th1 environment and produces detectable levels of IL-12 in the patient's plasma, without any IL-12 related toxicity.
Claims3
A method of treating a patient with a solid tumor, the method comprising:
- inducing the production of endogenous IL-12 in the patient, wherein the endogenous IL-12 is induced by administering a composition comprising activated allogeneic Th1 cells to the patient, wherein the Th1 cells are activated by cross-linking CD3 and CD28;
- ablating all or portion of the solid tumor in the patient to generate tissue necrosis along with intratumoral administration of the activated allogeneic Th1 cells;
- measuring the level of endogenous IL-12 in the patient;
- and
- readministering the composition until endogenous IL-12 in the plasma of the patient is at least about 5000 pg/ml.
2 more elements
Dependencies are inferred from the claim text.